BMEA vs. RGNX, SLDB, CTMX, FULC, INBX, MNPR, GLUE, CYRX, ITOS, and RAPT
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include REGENXBIO (RGNX), Solid Biosciences (SLDB), CytomX Therapeutics (CTMX), Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Monopar Therapeutics (MNPR), Monte Rosa Therapeutics (GLUE), CryoPort (CYRX), iTeos Therapeutics (ITOS), and Rapt Therapeutics (RAPT). These companies are all part of the "pharmaceutical products" industry.
Biomea Fusion vs. Its Competitors
REGENXBIO (NASDAQ:RGNX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.
88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Comparatively, 18.4% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
REGENXBIO has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500.
Biomea Fusion has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biomea Fusion had 7 more articles in the media than REGENXBIO. MarketBeat recorded 20 mentions for Biomea Fusion and 13 mentions for REGENXBIO. Biomea Fusion's average media sentiment score of 0.57 beat REGENXBIO's score of 0.37 indicating that Biomea Fusion is being referred to more favorably in the news media.
Biomea Fusion has a net margin of 0.00% compared to REGENXBIO's net margin of -112.70%. REGENXBIO's return on equity of -66.95% beat Biomea Fusion's return on equity.
REGENXBIO currently has a consensus price target of $28.38, suggesting a potential upside of 169.98%. Biomea Fusion has a consensus price target of $9.50, suggesting a potential upside of 413.51%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than REGENXBIO.
Summary
Biomea Fusion beats REGENXBIO on 12 of the 16 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
This page (NASDAQ:BMEA) was last updated on 10/8/2025 by MarketBeat.com Staff
